Latest Histone deacetylase Stories
WALTHAM, Mass., June 27, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that data from two entinostat clinical trials both based on tumor reprogramming will be presented at the International Association for the Study of Lung Cancer's (IASLC) 14th World Conference on Lung Cancer meeting (www.2011worldlungcancer.org) July 3 to 7 in Amsterdam, The Netherlands.
WALTHAM, Mass., June 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No.
A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found.
SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009.
SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc.
BellBrook Labs has developed a new HTS assay for screening methyltransferases, the family of enzymes involved in epigenetic modifications that cause cancerous cell growth and metastasis.
Tumor suppressor genes normally control the growth of cells, but cancer can spring up when these genes are silenced by certain chemical reactions that modify chromosomes.
Scientists have achieved one of the oldest and most rarely achieved goals of cancer researchâ€”they have found a way to â€œdistractâ€ cancer cells from their normal activities and make them act like normal cells.
WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.
A paper announcing a breakthrough discovery in the fight against Niemann-Pick Type C, coauthored by Olaf Wiest and Paul Helquist of the University of Notre Dame's Department Chemistry & Biochemistry and Frederick Maxfield, Chair of Biochemistry at Cornell University Weill College of Medicine, appears in the Proceedings of the National Academy of Sciences this week.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.